GlassScriptPhysician profile
Kendal Shrote
NPI 1760073456
$1,055.54
in general payments reported to CMS, 2019-2025
15 companies · $117 in 2025
The $117 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $294 · 2022: $163 · 2023: $185 · 2024: $296 · 2025: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $571 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $571.21 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $204.50 | 2022-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $130.54 | 2021-2022 | |
| Corium, LLC | $122.08 | 2023-2024 | Azstarys |
| Abbvie INC. | $105.35 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $95.64 | 2021-2024 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $85.27 | 2021-2025 | Rexulti |
| Alkermes, INC. | $77.03 | 2021-2024 | Aristada, Vivitrol, Vivitrol |
| Axsome Therapeutics, INC. | $74.83 | 2023-2024 | Auvelity |
| Tris Pharma INC | $34.24 | 2023-2024 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $28.49 | 2022-2025 | Qelbree |
| E.R. Squibb & Sons, L.L.C. | $27.27 | 2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $18.58 | 2024 | Austedo Xr |
| Lundbeck LLC | $18.58 | 2023 | Rexulti |
| Neos Therapeutics, LP | $17.02 | 2022 | |
| Ironshore Pharmaceuticals INC. | $16.12 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kendal Shrote listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.